NO993846L - Metode for deteksjon og lokalisering av maligne, humane tumorer - Google Patents
Metode for deteksjon og lokalisering av maligne, humane tumorerInfo
- Publication number
- NO993846L NO993846L NO993846A NO993846A NO993846L NO 993846 L NO993846 L NO 993846L NO 993846 A NO993846 A NO 993846A NO 993846 A NO993846 A NO 993846A NO 993846 L NO993846 L NO 993846L
- Authority
- NO
- Norway
- Prior art keywords
- detection
- composition
- relates
- malignant tumors
- pharmaceutical composition
- Prior art date
Links
- 238000001514 detection method Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000004807 localization Effects 0.000 title 1
- 230000003211 malignant effect Effects 0.000 title 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 abstract 6
- 101800001814 Neurotensin Proteins 0.000 abstract 4
- 102000050267 Neurotensin Human genes 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000003384 imaging method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 102000017922 Neurotensin receptor Human genes 0.000 abstract 1
- 108060003370 Neurotensin receptor Proteins 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 238000003748 differential diagnosis Methods 0.000 abstract 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 abstract 1
- 238000002595 magnetic resonance imaging Methods 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 229940121896 radiopharmaceutical Drugs 0.000 abstract 1
- 239000012217 radiopharmaceutical Substances 0.000 abstract 1
- 230000002799 radiopharmaceutical effect Effects 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/085—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being neurotensin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Radiation-Therapy Devices (AREA)
- Nuclear Medicine (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Peptides Or Proteins (AREA)
- External Artificial Organs (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Oppfinnelsen vedrører en fremgangsmåte for å detektere og lokalisere maligne tumorer og deres metastaser i vev som, i normal tilstand og i ikke-neoplastiske tilstander av kronisk inflammasjon, ikke inneholder vesentlige kvanta av neurotensinreseptorer i kroppen hos et menneske, som omfatter (i) administrering til nevnte menneske en sam- mensetning som omfatter, i et kvanta tilstrekkelig for ekstern avbildning,, et radiomerket peptid selektert fra gruppen bestående av neurotensin (NT), NT-reseptoragonister, NT- reseptorantagonister, NT-analoger og NT-derivater, og derved (H) utsette nevnte men- neske for ekstern avbildning ved radioaktiv scanning eller ved magnetisk resonansav- bildning, for å bestemme målstedene i kroppen hos nevnte vesen. Oppfinnelsen vedrører videre en metode for terapeutisk behandling av nevnte maligne tumorer ved administre- ring av det ovenfor definerte peptidet merket for dette formålet, og til differensiell dia- gnostisk bestemmelse og deteksjon av en spesifikk tumortype (dvs. eksokrin kanal- pankreatisk karcinom) i pankreas. Oppfinnelsen vedrører også en farmasøytisk sammensetning til bruk for deteksjon, en farmasøytisk sammensetning til bruk for terapi og et kitt for fremstilling av en radiofar- masøytisk sammensetning.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97200297 | 1997-02-03 | ||
| PCT/US1998/001964 WO1998033531A1 (en) | 1997-02-03 | 1998-02-02 | Method for the detection and localization of malignant human tumours |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO993846D0 NO993846D0 (no) | 1999-08-10 |
| NO993846L true NO993846L (no) | 1999-09-09 |
Family
ID=26146106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO993846A NO993846L (no) | 1997-02-03 | 1999-08-10 | Metode for deteksjon og lokalisering av maligne, humane tumorer |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6312661B1 (no) |
| EP (1) | EP0968001B1 (no) |
| JP (1) | JP2001511152A (no) |
| AT (1) | ATE253381T1 (no) |
| AU (1) | AU728712C (no) |
| CA (1) | CA2279530C (no) |
| DE (1) | DE69819478T2 (no) |
| HU (1) | HUP0001316A3 (no) |
| IL (1) | IL131386A0 (no) |
| NO (1) | NO993846L (no) |
| WO (1) | WO1998033531A1 (no) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3340699B2 (ja) * | 1998-06-05 | 2002-11-05 | 東京瓦斯株式会社 | 膵外分泌機能診断剤 |
| US7232559B1 (en) | 1999-06-04 | 2007-06-19 | Tokyo Gas Company Limited | Diagnostic agents for pancreatic exocrine function |
| AU2119101A (en) * | 1999-10-22 | 2001-05-08 | Insight Neuroimaging Systems, Llc | Ligand chelated paramagnetic mri contrast agents |
| US8175890B2 (en) * | 2001-10-30 | 2012-05-08 | Biodose, Llc | Pharmacy based method and algorithm for handling of radioactive pharmaceuticals and generating of reports therefrom |
| US7630907B2 (en) * | 2001-10-30 | 2009-12-08 | Biodose, Llc | Algorithm and program for the handling and administration of radioactive pharmaceuticals |
| US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| US20050100963A1 (en) * | 2002-03-01 | 2005-05-12 | Dyax Corporation | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
| US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
| US20040039241A1 (en) * | 2002-05-29 | 2004-02-26 | Biodose Llc | Integrated distribution and communication process and algorithm for providing, handling, distributing or generating reports regarding radioactive pharmaceuticals |
| WO2004009614A2 (en) * | 2002-07-24 | 2004-01-29 | The Salk Institute For Biological Studies | Receptor (sstr4)- selective somatostatin analogs |
| GR1004637B (el) * | 2003-04-04 | 2004-07-23 | Βιομεντικααλαιφασαιενσισαανωνυμηαεταιριααφαρμακευτικωναπροιοντωναα | Συνθεσηαβιολογικηακαιαπροκλινικηααξιολογησηααναλογωνανευροτενσινησα}@@bατροποποιημενωναμεαπαραγωγαατουα@ϊ@τετρααζαενδεκανιουα}@ϊ@tetraazaundecanebακαιαεπισημασμενωναμεατεχνητιο@mα}αηαλλααραδιονουκλιδιαατουατεχνητιουbαη@καιαρηνιο@ϊϊα}΄ηααλλααραδιονουκλιδιαατουαρηνιουbαγιααεφαρμογηαστηναογκολογιαα |
| WO2005027981A1 (en) * | 2003-09-17 | 2005-03-31 | Board Of Regents, The University Of Texas System | Mechanism-based targeted pancreatic beta cell imaging and therapy |
| US20060062729A1 (en) * | 2004-09-09 | 2006-03-23 | Carraway Robert E | Enhanced ligand binding to neurotensin receptors |
| US7507547B2 (en) * | 2004-09-09 | 2009-03-24 | University Of Massachusetts | Screening assays for antioxidants and antiproliferative compounds |
| EP2374003B1 (en) | 2009-01-07 | 2015-03-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment, the prognostic assessment and the detection of breast cancer |
| EP2454272B1 (en) * | 2009-07-16 | 2017-08-23 | IASON GmbH | Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors |
| US8378134B2 (en) | 2009-09-30 | 2013-02-19 | General Electric Company | Hydroxylated contrast enhancement agents |
| EP2740726A1 (en) | 2012-12-07 | 2014-06-11 | 3B Pharmaceuticals GmbH | Neurotensin receptor ligands |
| CN106794264B (zh) | 2014-06-10 | 2021-03-23 | 3B制药有限公司 | 包含神经降压肽受体配体的缀合物及其用途 |
| EP2954934A1 (en) | 2014-06-11 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand and use thereof |
| EP2954933A1 (en) | 2014-06-10 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2687680A1 (fr) * | 1992-02-20 | 1993-08-27 | Centre Nat Rech Scient | Procede de marquage de proteines et de peptides par acylation de leur fonction alpha aminee par un reactif comportant une fonction carboxylique activee. |
| WO1993018797A1 (en) * | 1992-03-25 | 1993-09-30 | Mallinckrodt Medical, Inc. | Method of intraoperatively detecting and locating tumoral tissues |
| CA2086453A1 (en) * | 1992-12-30 | 1994-07-01 | Mcgill University | Marker for neurotensin receptor |
| DE4337599A1 (de) * | 1993-11-01 | 1995-05-04 | Diagnostikforschung Inst | Metallbindende cysteinfreie Peptide für Diagnose und Therapie, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| WO1995022341A1 (en) * | 1994-02-18 | 1995-08-24 | Mallinckrodt Medical, Inc. | Labelled peptide compounds |
| FR2720066B1 (fr) * | 1994-05-20 | 1996-06-28 | Rhone Poulenc Rorer Sa | Peptides antagonistes de la neurotensine. |
| FR2722193B1 (fr) * | 1994-07-08 | 1996-10-04 | Sanofi Sa | Derives n-oxydes de 1-(7-chloro-4-quinoleinyl)pyrazole-3-carboxamides substitues, procede pour leur preparation et les compositions pharmaceitiques les contenant |
| WO1996023527A1 (en) * | 1995-02-03 | 1996-08-08 | Mallinckrodt Medical, Inc. | Method for the detection and localization of malignant human tumours |
-
1998
- 1998-02-02 EP EP98904839A patent/EP0968001B1/en not_active Expired - Lifetime
- 1998-02-02 WO PCT/US1998/001964 patent/WO1998033531A1/en not_active Ceased
- 1998-02-02 AT AT98904839T patent/ATE253381T1/de not_active IP Right Cessation
- 1998-02-02 JP JP53317698A patent/JP2001511152A/ja active Pending
- 1998-02-02 AU AU62622/98A patent/AU728712C/en not_active Ceased
- 1998-02-02 US US09/355,869 patent/US6312661B1/en not_active Expired - Lifetime
- 1998-02-02 CA CA002279530A patent/CA2279530C/en not_active Expired - Lifetime
- 1998-02-02 HU HU0001316A patent/HUP0001316A3/hu unknown
- 1998-02-02 DE DE69819478T patent/DE69819478T2/de not_active Expired - Lifetime
- 1998-02-02 IL IL13138698A patent/IL131386A0/xx unknown
-
1999
- 1999-08-10 NO NO993846A patent/NO993846L/no not_active Application Discontinuation
-
2001
- 2001-11-05 US US09/985,672 patent/US20020155064A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2279530C (en) | 2009-04-28 |
| ATE253381T1 (de) | 2003-11-15 |
| AU728712C (en) | 2001-07-19 |
| JP2001511152A (ja) | 2001-08-07 |
| US6312661B1 (en) | 2001-11-06 |
| IL131386A0 (en) | 2001-01-28 |
| DE69819478T2 (de) | 2004-09-02 |
| CA2279530A1 (en) | 1998-08-06 |
| AU728712B2 (en) | 2001-01-18 |
| EP0968001A1 (en) | 2000-01-05 |
| HUP0001316A2 (hu) | 2000-09-28 |
| EP0968001B1 (en) | 2003-11-05 |
| HUP0001316A3 (en) | 2001-10-29 |
| NO993846D0 (no) | 1999-08-10 |
| US20020155064A1 (en) | 2002-10-24 |
| AU6262298A (en) | 1998-08-25 |
| WO1998033531A1 (en) | 1998-08-06 |
| DE69819478D1 (de) | 2003-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO993846L (no) | Metode for deteksjon og lokalisering av maligne, humane tumorer | |
| Gonzalez et al. | Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states | |
| TW491854B (en) | Somatostatin peptides | |
| Parry et al. | In vitro and in vivo evaluation of 64Cu-labeled DOTA− linker− bombesin (7− 14) analogues containing different amino acid linker moieties | |
| US8691761B2 (en) | Somatostatin receptor 2 antagonists | |
| Laverman et al. | Targeting of a CCK2 receptor splice variant with 111In-labelled cholecystokinin-8 (CCK8) and 111In-labelled minigastrin | |
| KR0150478B1 (ko) | 방사성 표지된 소마토스타틴 유사체를 사용하는 펩티드/세포 수용체 역학을 이용한 신생조직의 원위치, 생체내 검출 및 식별방법 | |
| Stangelberger et al. | Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC‐3 and DU‐145 human androgen‐independent prostate cancers | |
| US20230099200A1 (en) | Radiolabeled peptides for non-invasive diagnosis and treatment of cxcr4 expressing tumors | |
| O'Byrne et al. | Somatostatin receptor expression in lung cancer | |
| N Eberle et al. | Synthetic peptide drugs for targeting skin cancer: malignant melanoma and melanotic lesions | |
| US9005575B2 (en) | Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same | |
| US10265425B2 (en) | Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same | |
| WO2021186060A1 (en) | Radiolabeled gastrin analogue for use in a method of treating and/or imaging cckb receptor positive diseases, in particular pulmonary and extrapulmonary small-cell carcinoma | |
| US9180214B1 (en) | Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer | |
| US20240245811A1 (en) | Alpha radiolabeled gastrin analogue and use thereof in methods of treating cckb receptor positive diseases | |
| Lamberts et al. | Somatostatin receptors: clinical implications for endocrinology and oncology | |
| Guo et al. | A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging | |
| US20190160188A1 (en) | Radiolabeled Alpha-Melanocyte Stimulating Hormone Hybrid Peptide for Melanoma Targeting | |
| US20230270893A1 (en) | Gallium-labeled gastrin analogue and use in a method of imaging cckb-receptor-positive tumors or cancers | |
| EP1208852B1 (en) | Neuropeptide Y1 receptor binding compounds in the treatment and diagnosis of cancer | |
| Giblin et al. | In vitro and in vivo evaluation of 111In-labeled E. coli heat-stable enterotoxin analogs for specific targeting of human breast cancers | |
| ES2307325T3 (es) | Metodo para aumentar la acumulacion en tejidos de compuestos raiomarcados. | |
| Zhao et al. | Treatment of transplanted tumor of lung adenocarcinoma A549 transfected by human somatostatin receptor subtype 2 (hsstr2) gene with 188Re-RC-160 | |
| TWI288751B (en) | Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |